

بسم الله الرحمن الرحيم





شبكة المعلومات الجامعية التوثيق الالكتروني والميكرو فيلم



جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار





بعض الوثائق الأصلية تالفة





بالرسالة صفحات
لم ترد بالأصل





THESIS SUBMITTED FOR PARTIAL FULFILMENT OF M.D. DEGREE IN Internal Medicine Department

Vascular Endothelial growth factor A in HCV infected patients before and after
treatment with DAAS and its possible relation to HCC development

Postgraduate Student: Ashraf Bekheet Salama

Degree: MSc Internal medicine -Tanta University

DIRECTOR: Essam Mohamed Bayoumy Helal

Academic Position: Professor

Department: Internal medicine

Co-DIRECTOR: Wesam Ahmed Ibraheem

Academic Position: Professor

Department: Internal medicine

Co-DIRECTOR: Moataz Mohamed Sayed

Academic Position: Professor

Department: Internal medicine

Co-DIRECTOR: Mohamed Magdy Salama

Academic Position: Lecturer

Department: Internal medicine

Co-DIRECTOR: Ahmed Mohamed EL Ghandour

Academic Position: Lecturer

Department: Internal medicine

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

﴿رَبَّنَا وَسِعْتَ كُلَّ شَيْءٍ رَّحْمَةً وَعِلْمًا فَاغْفِرْ لِلَّذِينَ

تَابُوا وَاتَّبَعُوا سَبِيلَكَ وَقِهِمْ عَذَابَ الْجَحِيمِ ﴿٧﴾

غافر: ٧

صدق الله العظيم

Dedication

To the soul of my

Father and mother

They give me everything, I gave them nothing

To my

Beloved wife

To all my family and friends who supported

and helped me during working on this

research



Acknowledgements

Before all, I would like to express my deep gratitude to ALLAH who blessed me with compassionate help to accomplish this work.

I wish to express my deep appreciation to **Prof. Dr. Essam Mohamed Bayoumy Helal** , Professor of Internal Medicine, Hepatology and Gastroenterology, Ain shams University for his close supervision, valuable instructions and continuous guidance and patience. He has generously devoted much of his time and effort to plan and supervise this study, making me feel great honor to work under his supervision.

I would like to express my sincere gratitude to **prof. Dr Wesam Ahmed Ibraheem**, Professor of Internal Medicine, Hepatology and Gastroenterology, Ain shams University for his sincere support, patience and guidance of this work.

I owe to **prof. Dr. Moataz Mohamed Sayed**, Professor of Internal Medicine ,Hepatology and Gastroenterology, Ain shams University for his support and guidance of this work.

Thanks a lot for **Dr. Mohamed Magdy Salama& Dr. Ahmed Mohamed EL Ghandour**, Lecturers of Internal Medicine , Hepatology and Gastroenterology, Ain shams University for their support.

LIST OF CONTENTS

Title	Page
List of abbreviations	III
List of tables	VI
List of figures	VII
Introduction and Aim of the work	1
Review of literature	
■ Hepatitis C virus	5
■ The possible Relation Between HCV Infection Treatment by DAAs and HCC Recurrence	31
■ Vascular endothelial growth factor	35
Patients and Methods	50
Results	53
Discussion	65
Summary	73
Conclusion and Recommendations	76
References	87
Appendices	110
Arabic Summary	١

LIST OF ABBREVIATIONS

Abbreviation	Meaning
AASLD	American Association for the Study of Liver Disease
AFP	Alpha-Feto Protein
ALB	Albumin
ALT	Alanine aminotransferase
ANRS	France Recherche Nord & Sud Sida-hiv Hepatites
AST	Aspartate aminotransferase
CBC	Complete Blood Count
CT	Computed Tomography
CYP3A	Cytochrome P450 3A
DAAs	Direct Acting Antivirals
DAC	Daclatasvir
EASL	European Association for the Study of the Liver
EC	Endothelial cells
ECG	Electrocardiography
ECHO	Echocardiography
EDTA	Ethylenediaminetetraacetic acid
eGFR	Estimated Glomerular Filtration Rate
ESRD	End Stage Renal Disease
FDA	Food and Drug Administration
FIB-4	Fibrosis-4
GT	Genotype
HCC	Hepatocellular Carcinoma
HCV	Hepatitis C Virus
HCV-Ab	Hepatitis C Virus Antibody
HCV-RNA	Hepatitis C virus Ribonucleic Acid

HB	Hemoglobin
HBs-Ag	Hepatitis B virus surface Antigen
HBV	Hepatitis B Virus
HD	Hemodialysis
HIF-1	Hypoxia inducible factor-1
HIV	Human Immunodeficiency Virus
IDU	Injection Drug Use
IL	Interleukins
INF	Interferon
INR	International Normalized Ratio
LDV	Ledipasvir
MICA/B	MHC class I Chain-related protein A/B
MHC	Major Histocompatibility Complex
MRI	Magnetic Resonance Imaging
MVI	Microvascular Invasion
NCCVH	National Committee for Control of Viral Hepatitis
NF-κB	Nuclear Factor KappaB
NKG2D	Natural killer group 2 member D
NLRP3	Leucine-Lich Repeat Protein-3
NNPIs	Non-Nucleoside Polymerase Inhibitors
NPIs	Nucleoside Polymerase Inhibitors
Nrp-1	Neuropilin-1
NS	Non-Structural
PCR	Polymerase Chain Reaction
PDGF	Platelet derived growth factor
Peg-INF	PEGylated Interferon

List of Abbreviations

PI3K	Phosphoinositide 3-kinase
PIs	Protease Inhibitor
PKB	Protein kinase B
PLGF	Placental growth factor
PLTs	Platelets
PT	Prothrombin Time
RBV	Ribavirin
RF	Radiofrequency
SMCs	Smooth cells
SMV	Simeprevir
SOC	Standard Of Care
SOF	Sofosbuvir
STAT3	Signal Transducer and Activator of Transcription 3
SVR	Sustained Virological Response
TACE	Transarterial Chemoembolization
TGF	Transforming Growth Factor
TNF	Tumor Necrosis Factor
TTT	Treatment
VEGF	Vascular endothelial growth factor
VPF	Vascular permeability factor
WBCs	White Blood Corpuscles
WHO	World Health Organization

LIST OF TABLES

Table No.	Title	Page No.
<i>Tables of Review</i>		
(I)	Classification of new antiviral drugs	11
<i>Tables of Results</i>		
1	Age distribution among studied group	59
2	Sex distribution among studied group	60
3	CBC distribution	61
4	Liver and kidney function distribution	61
5	Alfa fetoprotein distribution betweenstudied groups	61
6	VEGF distribution between studied groups	63
7	PCR distribution among HCV	60
8	ROC Curve for VEGF regard cutoff HCC	64
9	Follow up of VEGF level in HCV group	65
10	Correlation of VEGF with other HCV parameters in HCV&HCC groups	66
11	Distribution of VEGF among studied HCC with and without intervention	67
12	VEGF distribution among HCV at different times and HCC with and without intervention	69

LIST OF FIGURES

Figure No.	Title	Page No.
<i>Figures of review</i>		
(I)	Hepatitis C virus replicative cycle and main targets for direct acting antiviral agents	10
(II)	The Egyptian protocol for chronic hepatitis C infection	19
(III)	Inflammation is a hallmark of injured liver	21
(IV)	Schematic diagram illustrating the receptor - binding specificity VEGF family members signaling pathways	28
(V)	Model of vascular endothelial growth factor (VEGF)/Vegf receptors (VEGFR) role in tumor angiogenesis	39
<i>Figures of Results</i>		
1	Age distribution among studied group	60
2	Alfa fetoprotein distribution betweenstudied groups	62
3	VEGF distribution between studied groups	63
4	ROC Curve for VEGF regard cutoff HCC	64
5	Follow up of VEGF level in HCV group	65
6	Distribution of VEGF among studied HCC with and without intervention	68